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ABSTRACT 
While high levels of Pkd1 expression are detected in tissues of patients with autosomal dominant 
polycystic kidney disease (ADPKD), it is unclear whether enhanced expression could be a pathogenetic 
mechanism for this systemic disorder. Three transgenic mouse lines were generated from a Pkd1-BAC 
modified by introducing a silent tag via homologous recombination to target a sustained wild type 
genomic Pkd1 expression within the native tissue and temporal regulation. These mice specifically 
overexpressed the Pkd1 transgene in extrarenal and renal tissues from ~2- to 15-fold over Pkd1 
endogenous levels in a copy-dependent manner. All transgenic mice reproducibly developed tubular and 
glomerular cysts leading to renal insufficiency. Interestingly, Pkd1TAG mice also exhibited renal fibrosis 
and calcium deposits in papilla reminiscent of nephrolithiasis as frequently observed in ADPKD. Similar 
to human ADPKD, these mice consistently displayed hepatic fibrosis and ~15% intrahepatic cysts of the 
bile ducts affecting females preferentially. Moreover, a significant proportion of mice developed cardiac 
anomalies with severe left ventricular hypertrophy, marked aortic arch distention and/or valvular 
stenosis and calcification that had profound functional impact.  Of significance, Pkd1TAG mice displayed 
occasional cerebral lesions with evidence of ruptured and unruptured cerebral aneurysms. This Pkd1TAG 
mouse model demonstrates that overexpression of wildtype Pkd1 can trigger the typical adult renal and 
extrarenal phenotypes resembling human ADPKD.  
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INTRODUCTION 
Human autosomal dominant polycystic kidney disease (ADPKD) is one of the most prevalent 
monogenic diseases with an incidence of 1:400 to 1:1000 individuals. It is a multisystemic disorder 
characterized by numerous bilateral renal epithelial cysts affecting all segments of the nephron. 
Eventually, progression of these multiple cysts in kidneys leads to renal insufficiency and end-stage 
renal disease by late mid-age. Extrarenal clinical manifestations are also common with hepatic cysts 
being the most frequent, and predominately so, in women. Non-cystic features include cardiac and 
valvular anomalies and, less frequently, intracranial aneurysms (1).  
 
The majority of patients (85-90%) with ADPKD have a mutation in the PKD1 gene. The gene spans 
54kb and encodes a very large protein of 4302 amino acids, polycystin-1. Polycystin-1 is a 
transmembrane protein that has a large N-terminal extracellular domain with a unique combination of 
motifs and was reported to undergo partial autocleavage at the G-protein coupled receptor proteolytic 
site (GPS) (2). Polycystin-1 has been implicated in signal transduction, in mechanosensation, and in 
cell-cell/cell-matrix interactions. Human PKD1 and polycystin-1 expression have been analyzed in 
normal and ADPKD tissues. PKD1 and polycystin-1 are normally expressed in a wide range of adult 
tissues including epithelial and non-epithelial cell types (3-8). Interestingly, PKD1 expression is 
developmentally regulated, particularly in the kidneys. Polycystin-1 has highest levels in fetal life and is 
readily detected in glomerular and tubular epithelial cells (reviewed in (9) and reference therein). In 
normal adult kidneys, the RNA transcript and protein levels of polycystin-1 are decreased to lower 
levels, most notably in the collecting and distal tubules. By contrast, PKD1 expression levels were 
increased (~2-fold) in ADPKD kidneys (3, 10) and consistently, the majority of renal epithelial cysts 
displayed persistent or enhanced levels of polycystin-1 (4).  
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Although ADPKD is a dominant disease, the stochastic nature of the renal cysts in ADPKD suggests 
that the mutational mechanism for PKD1 could result from a two-hit phenomenon or a loss of 
heterozygosity. This mechanism is supported by detection of PKD1 clonal somatic mutations in cells 
from a significant proportion of cysts (11-13). Moreover, loss of heterozygosity could account for the 
widely varying phenotype commonly observed in individual families. This mechanism would however 
be at variance with the persistent or enhanced expression of PKD1 seen in the majority of human renal 
cysts, unless a mechanism of gain-of-function/overexpression may also be operant.  
 
The mouse Pkd1 gene has very close similarities to the human PKD1 and may provide important 
insights into PKD1 function(s). During normal development, murine Pkd1 is expressed at high levels 
from the morula stage and detected in all neural crest cell derivatives including adult brain, aortic arch, 
cartilage, and mesenchymal condensation (14, 15). Homozygous mutant mice targeted for Pkd1 deletion 
have been reported to develop renal and pancreatic cysts (16-21). These attempts to generate mouse 
models, unfortunately, did not produce viable animals. Nevertheless, the occurrence of renal cysts in 
these homozygous Pkd1 mutant mice would be consistent with the hypothesis of a two-hit mutational 
mechanism in humans that involves a germline mutation and somatic inactivation of the normal allele. 
This mechanism is also supported by conditional ablation of Pkd1 in mice few days after birth (22) but 
not upon later ablation since cysts developed only focally (23, 24). However, evidence of a mechanism 
of haploinsufficiency or gene dosage reduction for cystogenesis was provided in mice homozygous for a 
Pkd1 hypomorphic allele or heterozygous for a Pkd1 deleted allele (25, 26). Moreover, Pkd1 gain of 
function may also be an additional mechanism for ADPKD pathogenesis as determined by the renal-
targeted Pkd1 in SBPkd1TAG mice with renal cystogenesis (27). These findings would support a gene 
dosage dependent mechanism for ADPKD where mutations of loss of heterozygosity, 
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haploinsufficiency, or overexpression could trigger a renal phenotype and thereby provide an 
explanation for the high penetrance found for a range of different mutations in this disease. 
 
To interrogate increased Pkd1 dosage as an ADPKD pathogenetic mechanism, Pkd1 in the native 
genomic context purified from a murine BAC was targeted in transgenic mice. We generated three 
transgenic lines that expressed systemically increase Pkd1 at proportional gene dosage levels in different 
tissues. These mice not only develop polycystic kidneys and renal failure but also all the prevalent 
extrarenal manifestations observed in ADPKD patients including liver cysts, cardiac and valvular 
anomalies as well as the dreadful complication of ruptured intracranial aneurysms. Our study reproduces 
the first orthologous ADPKD mouse model with the entire spectrum of adult extrarenal and renal 
phenotypes. 
 
RESULTS 
Production of Pkd1TAG-BAC by homologous recombination 
To investigate the role of Pkd1 overexpression/gain-of-function in renal and extrarenal tissues, we have 
used a genomic clone containing the entire Pkd1 gene in a BAC vector 129/Sv library that we previously 
isolated (27). This BAC contains a ~121kb insert with ~37kb of upstream and ~39kb of downstream 
sequences of the Pkd1 gene including the entire adjacent Tsc2 gene. This Pkd1-BAC was modified by 
two successive homologous recombination events. First, the Pkd1 gene was tagged in exon 10 by 
substituting a nucleotide (G to A) to create a novel EcoRI site at position 2355 on the cDNA map. This 
silent point mutation was produced to readily distinguish the Pkd1 gene and transcript of the BAC from 
that of endogenous origin. Second, we have deleted the Tsc2 gene (~34.5kb) of the Pkd1-BAC to 
prevent introducing the Tsc2 gene exogenously and to reduce the BAC size (Figure S1).  This new 
Pkd1TAG-BAC was digested with MluI, a unique site located at ~24.8kb upstream of the Pkd1 translation 
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initiation site, and NotI site in the BAC polylinker sequences to remove the prokaryotic BAC vector 
sequences (Supplemental Figure 1, Figure 1). This ~75kb MluI-NotI fragment was isolated, purified and 
quantified for oocytes microinjection (28). 
Production and analysis of Pkd1TAG transgenic mice 
Three transgenic founders carrying several copies (2 to 15) of the Pkd1TAG transgene as determined by 
Southern analysis, served to derive three transgenic lines. Characterization of the transgene 
chromosomal integrity in these lines was performed with 5’, internal, and 3’ probes (a to g) used for 
BAC analysis in Supplemental Figure 1. Transgene 5’ flanking sequence was monitored for presence of 
a specific polymorphism from the 129/Sv genetic background by a band at 100bp compared to the 
113bp and/or 133bp typical of the inbred C57Bl/6J and CBA/J strains used to produce these transgenic 
mice (Figure 1). To verify the transgene 3’ end, a probe consisting of the Pkd1 gene exon 45-46 was 
used to detect the endogenous 7.0kb Pkd1 band as well as the transgene 5.0kb (Figure 1). The Pkd1TAG 
mice contained complete copies of the Pkd1 transgene based also on the internal genomic overlapping 
structure analysis. 
 
Pkd1 expression in adult Pkd1TAG transgenic mice 
Analysis of Pkd1TAG transgene and Pkd1 endogenous gene expression was carried out in several tissues. 
To first quantify the transcript levels from the transgene comparatively to the endogenous gene, 
Northern blots were performed on kidneys (n=4) of each transgenic line (Figure 2A). The transgene 
transcript size was identical to the endogenous transcript of 14.2kb. All Pkd1TAG transgenic mice 
showed systematically increased transcript Pkd1 levels in kidneys relative to controls. In fact, Pkd1TAG 
transgene renal expression increased with the number of Pkd1TAG copies (2, 6, 15) in each line compared 
to controls (n=2): line 6 (n=4), 18 (n=3), 26 (n=3) displayed ~1.9±0.8, 6.0±0.9 and 17.9±1.9 fold 
increase respectively. 
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Quantification of transgene expression levels was carried out by real-time PCR in the three transgenic 
lines at adult age, by using primers in the exon 1 and 2 of Pkd1 (Figure 2B). The Pkd1TAG expression in 
transgenic mice was compared to S16 ribosomal protein gene product as internal standard. Analysis of 
Pkd1 renal expression showed similar fold increase for transgenic kidneys as those obtained by Northern 
blot. Since endogenous Pkd1 expression levels are modulated in various tissues, we quantified Pkd1TAG 
expression levels to determine whether the transgene followed the endogenous gene expression pattern. 
Transgene expression by real-time PCR consistently and specifically showed highest expression in the 
brain of all transgenic lines relative to other organs (Figure 2B). The heart, lung, and brain displayed 
higher Pkd1 levels than in the kidneys whereas the other organs including spleen, liver, and pancreas 
levels were lower. Interestingly, the three transgenic lines demonstrated, within all tissues analyzed, a 
comparable increase in transgene to endogenous expression, indicating that the Pkd1TAG transgene 
contained all the appropriate regulatory elements for tissue expression.  
To monitor whether gene expression correlated with the levels of Pkd1 protein or polycystin-1 (Pc-1), 
Western blot was performed on various tissues of the Pkd1TAG26 line using the 7e12 Pc-1 monoclonal 
antibody and Gapdh as control. The Pkd1TAG26 showed several fold increase of Pc-1 for all extrarenal 
and renal tissues relative to non-transgenic control mice (Figure 2C). Subsequently, phenotype caused 
by transgene expression was characterized in the Pkd1TAG mice by gross and histology analysis of 
tissues frequently affected in human ADPKD. 
  
Renal anomalies in Pkd1TAG mice  
Pkd1TAG transgenic adult kidneys of all three lines were generally pale and exhibited bilateral cysts 
studding the cortical surface. Histologically, transgenic mice developed multiple microscopic and 
macroscopic cysts affecting cortex and medulla as well as glomerular cysts (Figure 3A-F). Anomalies 
were detected at 1 month of age for Pkd1TAG 6 and 26 mice as mild tubular dilatation and scattered 
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tubular microcysts with epithelial hyperplasia respectively, suggesting abnormal features early on as 
observed in ADPKD patients. The renal phenotype in Pkd1TAG 26 developed much more rapidly than in 
the Pkd1TAG 6 mice. Consistently, Pkd1TAG 26 kidneys at 2-months had tubular and glomerular cysts that 
became very severe by 3-months of age whereas Pkd1TAG 6 displayed glomerular and tubular dilatation 
at 7 months of age that progressed to cysts at 9 months and were severely cystic by 12-16 months of age. 
Cystic and even non-cystic tubules frequently displayed epithelial hyperplasia and hypertrophy and 
occasional presence of polyps with variable severity between mice. Hemorrhagic cysts consistent with 
some hematuria, proteinaceous casts in tubular cysts as well as interstitial fibrosis were commonly 
observed (Figure 3B). To evaluate levels of fibrosis, we quantified the density of Sirius red staining in 
Pkd1TAG6 (n=6, 7-16months) at 5.7% and 26 kidneys (n=6, 2-8months) at 9.6% that was markedly 
elevated by ~4.8- and 8-fold respectively compared to controls (n=5; 1.2%). Further, partial and total 
sclerosis of glomeruli was detected in all three transgenic lines. To define more precisely the origin of 
the renal cysts, we used specific nephron segment markers of the proximal, distal, and collecting 
tubules. As shown in Figure 3C and D, cysts originated from all segments of the nephron with highest 
and similar proportion in proximal and collecting tubules (~30-35%). A significant proportion of cysts 
(~20%) were unstained, some of which with presence of mesangial tuft could be identified of glomerular 
origin whereas others could be from undifferentiated tubular epithelial cells. Analysis of Pkd1TAG26 
mice (7/18) with highly invasive renal cysts also displayed calcium deposits that were mainly localized 
to the papilla, reminiscent of the renal calculi described frequently in ADPKD (29-31) (Figure 3E versus 
F). Since we observed the presence of renal epithelial hyperplasia and polyps, we monitored cell 
proliferation with the nuclear antigen Ki67 marker by immunostaining in Pkd1TAG 6 and 26 lines (Figure 
3G, H). Proliferation was calculated as a percentage of tubules with 0, 1 or ≥2 Ki67-positive cells in the 
kidneys. In control animals, >92% of tubules (n=941) had no Ki67-positive cells and 5.4% or 2.1% of 
tubules displayed 1 or ≥2 positive cells respectively. By contrast, the Pkd1TAG 26 line displayed 22.6% 
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and 27.5% of cystic tubules with 1 and ≥2 Ki67 positive cells, a significant increase of 4 to 10-fold 
relative to controls (p<0.01). Similar levels of proliferation were also observed for the Pkd1TAG 6 line 
(16% and 26% of 1 and ≥2 Ki67 positive cells).  To determine whether c-myc is implicated in the 
Pkd1TAG renal phenotype, c-myc expression was analyzed by real-time PCR and immunohistochemistry. 
Expression of c-myc was increased by ~4.8-fold in the Pkd1TAG 26 mice (n=4) relative to controls (n=4) 
(≤0.02). Consistently, renal sections of Pkd1TAG 6 and 26 mouse lines also revealed diffusely elevated 
levels of c-myc relative to controls and frequently more pronounced nuclear staining in cystic epithelium 
(Figure 3I, J), suggesting that c-myc could be an indirect effector of Pkd1TAG.  
 
Since cilia anomalies have been associated with cyst formation, cilia of renal epithelial cells were 
monitored by α-acetylated tubulin staining in Pkd1TAG 26 line and control mice at few weeks of age 
prior to overt cystogenesis (Figure 3K, L). Most strikingly, the cilia size distribution (at 1 µm interval) 
in all Pkd1TAG mice showed significantly longer cilia length relative to controls (Figure 3L). Indeed, 
most cilia of the Pkd1TAG mice (n=346) (Figure 3L) were >5 µm whereas cilia in controls (n=266) 
(Figure 3K) were mainly 2-3 µm in length. Cilia from Pkd1TAG renal epithelium were often of kinky 
structure and occasionally displayed 2 or multicilia by EM. These mice consistently developed PKD 
features pointing to the induced expression from the transgene as specifically responsible for the 
pathogenesis. 
 
Altered renal physiology in Pkd1TAG mice 
Renal function was monitored in the low and high expressor Pkd1TAG 6 and 26 transgenic lines. Animals 
were monitored for urinary levels of urea nitrogen, creatinine, protein, and urine osmolality and volume 
(Table 1). In comparison to negative controls of same genetic background, the low and high expressors 
exhibited significant increase in urine volume similar to the positive PKD controls SBM mice (28). 
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These urinary and blood analysis are consistent with mild concentrating defects but cannot exclude AVP 
deficiency. Accordingly, urinary urea nitrogen, creatinine, and protein were significantly decreased. In 
addition, Pkd1TAG mice had urinary calcium (0.8±0.2; n=8, 9-14 months) and urinary pH (6.0±0.1, n=16, 
7-18 months) comparable to controls (0.9±0.2; n=4, 11 months) (5.9±0.1, n=4, 11 months). Mice from 
all three Pkd1TAG lines were also monitored for hematocrit levels since patients with progressive renal 
insufficiency commonly develop anemia. Consistently, the three Pkd1TAG mouse lines at 5 to 7 months 
of age displayed significantly reduced hematocrit levels (Table 1 and data not shown). Mice from the 
three transgenic Pkd1TAG lines were also analyzed qualitatively for proteinuria from urine samples on 
SDS-PAGE (Figure 4 A). Despite the reduced concentration level of protein in urine, Pkd1TAG animals 
at 4 months of age appeared to display non-selective proteinuria that was most pronounced in the high 
transgene expressor.  To determine whether Pc-1 in Pkd1TAG26 transgenic mice were present in urine, 
we prepared total crude protein from urine (T), urine devoided of exosome or uromodulin aggregates 
(supernatant 1, S1), the resuspended pellet was separated in two additional fractions the surpernatant 
containing uromodulin (supernatant 2, S2) and urinary exosome following the protocol of (32, 33). 
Western analysis of total crude urinary protein with the LRR Pc-1 antibody (7e12) showed a similar 
pattern to that of total kidney extracts from native untreated (N) and deglycosylated (DG) samples 
(Figure 4B). While samples in the native form displayed two protein bands estimated by migration at 
~360-380kDa and slightly above ~420kDa, in the deglycosylated form a unique product was detected 
corresponding to the lower band. Pc-1 was detected in three urine fractions (T, S1, and exosomes) 
whereas it appears absent in the supernatant (S2) for both control and transgenic mice. In exosomal 
pellet fraction, Pc-1 was present mainly in the glycosylated form, as observed in human ADPKD urinary 
exosomes (33). Interestingly, significant proportion of Pc-1 was also found in the S1 supernatant in both 
Pkd1TAG transgenic mice and controls in both glycosylated and unglycosylated forms, suggesting that 
the N-terminal domain of Pc-1 is likely excreted in the urine. Importantly, similar fold enrichment in Pc-
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1 was observed in Pkd1TAG26 transgenic mice relative to controls in all three Pc-1 containing fractions, 
indicating that the Pc-1 from the transgene follow a normal physiological process.  
 
Hepatic anomalies in Pkd1TAG mice similar to PKD 
Since human ADPKD frequently developed biliary dysgenesis, we investigated whether enhanced 
Pkd1TAG gene expression could induce hepatic abnormalities in mice. Readily from macroscopic 
liver examination, hepatic cysts could be detected in both transgenic 6 and 26 lines (low and high 
Pkd1 expressors): 5 of 34 Pkd1TAG transgenic mice from line 26 and in 1 of 32 from line 6 (Figure 
5A, B). Histologically, these liver developed cysts likely of cholangiocyte origin that ranged from 
mild to very severe (Figure 5C, D). Interestingly, these characteristic cystic features affected mainly 
female mice (4 out of 5) as in human ADPKD. Further, hepatic parenchyma from both transgenic 6 
and 26 lines showed presence of a broad band of fibrosis along the intrahepatic ducts that was 
systematically observed and in some mice, fibrosis was widespread (Figure 5E, F). Quantification of 
fibrosis over the liver sections showed ~4- to 5-fold increased respectively for the Pkd1TAG 6 
(9.8±9.3%; n=10; p≤0.02) and 26 lines (11.1±7.9%; n=12; p<0.002) compared to controls 
(1.9±0.8%; n=10). Similar to Pkd1TAG 6 and 26 renal analysis, we evaluated whether proliferation 
could be implicated in the hepatic cysts, liver sections were stained with Ki67. The epithelial linings 
of cysts were uniformly delineated by enhanced Ki67 staining and/or by strong nuclear staining 
(Figure 5G, H). These Pkd1TAG livers also displayed elevated c-myc expression in the cystic areas 
with more intense signal in cell lining the cysts (Figure 5I, J). Interestingly, this increased 
proliferation and myc expression paralleled the marked fibrosis in regions of liver cysts. Since the 
Pkd1TAG 6 and 26 transgenic mice develop typical hepatic ADPKD characteristics, it is likely that 
Pkd1 overexpression in the liver may be a pathogenetic mechanism through potentially modulating 
c-myc.  
12 
 
Cardiac anomalies in Pkd1TAG mice 
Because a proportion of ADPKD patients develop cardiac anomalies, we performed physiologic 
studies using non-invasive ultrasound imaging in Pkd1TAG 6 and 26 relative to control mice (Figure 
6A, B; Table 2). The M-mode dimensions showed significantly increased left ventricular posterior 
wall thickness at diastole and at systole indicating left ventricular hypertrophy (Table 2A). The 
interventricular septa thickness was also increased. Further, the aortic root diameter and area were 
significantly increased in the Pkd1TAG mice showing important dilatation as described in ADPKD 
patients. At necropsies, gross heart anatomy of mice from the three Pkd1TAG lines showed significant 
and extensive enlargement relative to that of negative control littermates (Figure 6C, D; Table 2A), 
providing evidence of eccentric dilated cardiac hypertrophy. Hearts of Pkd1TAG relative to controls 
also showed important alteration in the cardiac structure and morphology as analyzed by Microfil 
casting that fills the body entire vasculature providing a three-dimensional visualization of organ 
circulation (Figure 6E, F). Substantial abnormalities of the ventricular vasculature were readily 
detectable under different angles, suggesting injury to the myocardium with possible development of 
fibrosis (Figure 6F vs E). We then verified by histology and detected that 35-40% of Pkd1TAG mice 
(lines 18 and 26) displayed to 2-to 4-fold increase in cardiac fibrosis. 
 
Functional analysis by echographic measurements consistently showed a marked increased in stroke 
volume as well as in the cardiac output by almost 2-fold in Pkd1TAG26 mouse lines (Table 2B). While 
the heart rates of Pkd1TAG and control mice were similar, cardiac valves displayed some anomalies in 
the Pkd1TAG mice (Table 2B) (Figure 6A, B). As shown in Table 2, the significant increase in mean and 
peak velocity downstream of the aortic valve suggested stenosis. This increased velocity measurement 
was consistent with the abnormal aortic valve leaflets detected by ultrasound imaging as opaque in some 
Pkd1TAG 6 and 26 mice rather than delicate and translucent (Figure 6B). Upon heart sectioning, large 
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areas within the ventricular lining exhibited change in pigmentation, indicative of ventricular lining 
calcification (Figure 6G, H). To determine whether the valves opacity and ventricular lining anomalies 
resulted from calcium deposits, cardiac histologic sections were stained individually with Alizarin and 
VonKossa. Analysis revealed presence of calcification in 6 of the 15 aortic valves, 4 of which also had 
staining in ventricular lining (Figure 6I, J). Furthermore, 3 of these 6 Pkd1TAG mice exhibited staining in 
the myocardium as well. Since observations of valvular, vascular, and myocardium calcification in 
individuals with chronic kidney disease has been associated with higher serum phosphate (34), we 
determined the levels of phosphate in serum of Pkd1TAG mice. Analogously to human, the Pkd1TAG mice 
(1.9±0.3 mmol/L; n=8) had significantly increased serum phosphate relative to controls (1.4±0.2 
mmol/L; n=4), supporting the hypothesis that elevation in serum phosphate concentration may 
contribute to calcification risk and cardiovascular events.  
 
Vascular anomalies in Pkd1TAG mice  
To investigate whether adult Pkd1TAG mouse lines exhibited altered cardiovascular response, we 
measured blood pressure in two Pkd1TAG lines (26 and 18) and control mice using the tail cuff method. 
Two groups of Pkd1TAG mice were readily distinguishable in both lines. In Pkd1TAG26 line (6-7 months 
of age), the first group of mice (n=5) exhibited systolic blood pressure at 113.5±11.0 mmHg comparable 
to control mice (n=4) of systolic blood pressure at 116.2± 3.1 mmHg. The second group of Pkd1TAG 26 
mice (n=3) had significantly increased blood pressure at 161.1±5.1 mmHg (p<0.001).  Similarly, 
evidence of hypertension in two of six Pkd1TAG18 mice (132.3±1.3 mmHg; p<0.0009) indicated that the 
Pkd1TAG mouse lines can progress to severe hypertension as in human ADPKD. 
 
Upon signs of distress in three mice of Pkd1TAG 26 line, we macroscopically observed severe 
hemorrhage and severe intracranial edema. These mice at dissection did not show closure of the cranial 
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bone at the sutura sagitalis and have evidence of hydrocephalus with ventricle dilatation (Figure 7A and 
B). No control mice exhibited this phenotype. In the Pkd1TAG 26 mice, subarachnoid hemorrhages were 
observed in different areas of the brain and were so severe in some cases that a significant portion of the 
brain was completely destroyed/obliterated.  Further, the cerebellum of these Pkd1TAG 26 mice at 
histologic examination was underdeveloped, reduced in size or constricted, providing signs of prior 
compression of this region and adjacent structures (Figure 7D). To visualize and analyze the vasculature, 
we introduced Microfil casting to model the entire vasculature of Pkd1TAG 26 (n=5) and control (n=7) 
mice. As illustrated in Figure 7E-F, two Pkd1TAG26 mice compared to none in controls showed 
unruptured cerebral aneurysm, the most dreadful complication of ADPKD.  
 
Lifespan in Pkd1TAG mice  
Lifespan of mice from the three transgenic Pkd1TAG lines was also quantified. Animals died at 5.5 ± 2.8 
months (n=18) for the high expressing Pkd1TAG 26 line presumably due at least in part to renal failure, at 
older age of 16.7±5.5 months (n=9) and 16.6±1.8 months (n=12) for the lower expressors Pkd1TAG 18 
and 6 lines respectively. 
 
DISCUSSION 
This study reports generation and characterization of the first Pkd1 mouse model of ADPKD that 
develops the typical renal and extrarenal pathologic spectrum. This model was produced by expressing a 
“wild type” full length Pkd1 gene and proximal regions purified from a BAC that produces a functional 
polycystin-1 (Pc-1) protein. Since this mouse model reproduces both the entire phenotypic spectrum and 
at the similar frequency occurrence as in ADPKD, a systemic Pkd1 enhanced expression is most likely a 
pathogenetic mechanism.  
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The three transgenic Pkd1TAG mouse lines generated showed a copy-number dependent expression of the 
full-length Pkd1 transgene in all tissues. Since the regulatory pattern of transgene expression was similar 
to that of the endogenous gene, it is likely that the transgene includes all the necessary transcriptional 
regulatory regions of the Pkd1 gene. Consistently, the Pc-1 protein is also similarly overexpressed in 
these mice. Of importance, gene dosage or expression correlated with the progression of phenotypic 
severity. 
 
The Pkd1TAG mice are the first model among the mice with dysregulated or mutated Pkd1 gene that 
develops the typical multicystic “bosselated” cortical surface with tubular and glomerular cysts as in 
ADPKD. Renal insufficiency was detected in Pkd1TAG mice at 5-6 months of age by altered urinary and 
blood analysis. Severe cystogenesis with loss of renal function and increase kidney fibrosis are 
hallmarks of ADPKD renal pathology. In addition to frequent hemorrhagic cysts and hematuria, an 
incidence of ~39% of Pkd1TAG mice with pronounced cystic disease displayed intraluminal but also 
parenchymal calcium deposits limited to the papilla. Presence of this localized nephrocalcinosis in 
Pkd1TAG mice is compatible with the nephrolithiasis observed in 20-36% of patients with ADPKD (30, 
31). While the mechanism responsible for these calcium deposits is unknown, the urinary concentration 
defect should in theory have a protective effect but urinary stasis within the distorted anatomy and 
compressed tubules may predispose to calcium precipitation. 
 
Of particular interest was the significantly longer primary cilium of renal epithelial cells in Pkd1TAG 
prior to cyst appearances. This indicated that increased expression of normal functional polycystin-1 
protein might promote ciliogenesis. Since endogenous Pc-1 was localized to the cilia (35), this finding 
suggests that it can occur via a direct effect of Pc-1 overexpression and/or through indirect Pc-1 cellular 
effectors modulating proteins of the cilia and axoneme assembly. Since cilia anomalies preceded 
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cystogenesis, it raises the question whether it is a prerequisite for cyst formation in Pkd1TAG mice. In 
addition, the increased cilia length distribution also persisted during cystogenesis and this, in spite of 
significantly elevated renal epithelial proliferation. While defects in the primary cilia have been 
observed in other cystic diseases, most of cilia anomalies have been attributed to shorter or absence of 
cilia (35-38) except for the Nek8 and p75/cux genes (39, 40). 
 
The consistent increase in Pc-1 in equivalent proportion from crude urine to subfractionated exosomes 
of the Pkd1TAG over control mice argues that Pc-1 in transgenic kidneys undergoes the normal in vivo 
physiologic protein processing. The shed Pc-1 protein both glycosylated and unglycosylated in crude 
urine corresponded approximately in size to a N-terminal cleaved form of Pc-1 at the G protein-coupled 
receptor proteolytic site (GPS at aa 3041). Strikingly, similar size Pc-1 glycosylated and unglycosylated 
forms were free in urine itself whereas only the glycosylated form was detected in the exosome fraction. 
This finding is consistent with the cleaved form of PC-1 present in human urinary exosomes (33, 41). 
While the role of Pc-1 in exosomes remains to be elucidated, we speculate that the increased frequency 
of interaction between free Pc-1, exosome and cilia in flow of Pkd1TAG mice could influence 
intercellular and intracellular signaling. Alternatively, exosomes if in close proximity of cilia as shown 
in vitro (33) could interact, fuse and consequently, induce longer cilia with profound impact on 
mechanosignaling and tubular integrity.  
 
The spectrum of extrarenal phenotypes in the Pkd1TAG mice closely recapitulates that of human ADPKD. 
Indeed, the high frequency of hepatic cysts in Pkd1TAG mice affecting mainly females is reminiscent of 
ADPKD. Cysts affecting intrahepatic bile ducts are consistent with the endogenous pattern of Pkd1 
expression (14, 16) and likely due to enhanced transgene expression in Pkd1TAG mice. The systematic 
increased fibrosis surrounding the biliary ducts in Pkd1TAG mice indicated that fibrosis precedes cyst 
formation. Furthermore, it also suggests that Pkd1 overexpression interferes with the extracellular 
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environment and results in active remodeling of the extracellular matrix. Regions of hepatic cysts and 
fibrosis were associated with elevated proliferation. Interestingly, such association of liver fibrosis and 
cyst development has also been observed when Pkd1 gene dosage expression is reduced from a 
hypomorphic allele (42).  
 
The concomitant features of fibrosis and cyst formation in the liver and in kidneys of Pkd1TAG mice 
correlated with substantial stimulation of proliferation. Such phenotypic similarities to the SBM 
transgenic mice (43) produced by targeted c-myc expression prompted analysis of c-myc expression in 
liver and kidneys of Pkd1TAG mice. This study demonstrates that Pkd1 overexpression activates c-myc in 
both tissues and with a higher signal in cysts. Hence, it is likely a critical component of this signaling 
event. While the molecular mediators immediately downstream of Pkd1 protein are not yet delineated, c-
myc appears to play a central role in the signaling pathway cascade triggered by Pkd1.  
 
Cardiovascular anomalies are the most prevalent non-cystic extrarenal manifestation of ADPKD and of 
Pkd1TAG mice. Pkd1TAG mice structural cardiac defects are consistent with enhanced Pkd1 transgene 
expression following the Pkd1 endogenous pattern. We and others have shown that endogenous Pkd1 
expression was high in the aortic arch, valve leaflets, atrioventricular cushion, and low in myocardium 
of wild type mice (8, 14-16, 44). Accordingly, the generalized cardiac anomalies in Pkd1TAG transgenic 
mice included frequent left ventricular hypertrophy, thickening of the myocardial wall associated with 
significantly increased aortic root dilatation. In addition, the cardiac aortic and mitral valve morphologic 
anomalies, particularly stenosis and calcification revealed severe functional impact and suggested signs 
of valvular regurgitation. In fact, this would be consistent with a compensatory mechanism of heart 
dilatation/cardiomegaly and increased cardiac output with similar heart rate. In parallel to these 
anomalies, systemic hypertension in Pkd1TAG mice could be responsible indirectly for the marked aortic 
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insufficiency as well as the cardiac hypertrophy. However, the strong Pkd1 expression in the aortic 
valve and root is likely to have a direct contributory role. Together, these cardiac and aortic anomalies 
with important complications are analogous to those of ADPKD patients (45, 46).  
 
Probably the most devastating extrarenal manifestation in ADPKD is intracranial aneurysm. Given that 
Pkd1 is expressed in endothelial cells and vascular smooth muscle (8, 47), the presence of cerebral 
aneurysms in Pkd1TAG was consistent with a primary defect in vascular structure. Similarly, this Pc-1 
expression may also be the cause of hypertension independently of renal cystogenesis. Development of 
cerebral aneurysms in Pkd1TAG mice as in humans is asymptomatic and could be exacerbated by 
systemic hypertension. However, rupture of aneurysms was detected in a few Pkd1TAG mice at one 
month of age upon very brief exposure, if any, to hypertension. Rupture of cerebral aneurysms was 
evident by compression of adjacent structures, focal brain ischemia, and subarachnoid hemorrhage as 
well as by morbidity.  
 
Systemic enhanced expression of Pkd1TAG mice leads to abnormalities in various organs/tissues as well 
as in kidneys. Anomalies in a particular organ of Pkd1TAG mice likely result from direct expression of 
Pkd1 in this organ per se. Evidence for this direct effect instead of a secondary consequence of renal 
defects, is provided by the renal-targeted Pkd1 mice, SBPkd1TAG, that essentially displays a renal 
restricted PKD disorder (27) similar to that of Pkd1TAG kidney phenotype. 
 
The mutational mechanism of ADPKD was initially proposed as a two-hit model for cyst formation and 
thereby could explain the focal nature of cyst and the disease variable severity. However, this 
mechanism is at variance with the continuing expression of PKD1/PC-1 in the majority of ADPKD renal 
cysts (3-5, 10, 48-50), hepatic cysts (6, 44, 51), and cerebral aneurysms (47). A more inclusive model 
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would be that an imbalance or dysregulated PKD1/PC-1 would be sufficient to elicit a cystic phenotype. 
This model is supported by the increase in disease severity correlating with the increase Pkd1 gene 
dosage in Pkd1TAG and SBPkd1TAG mice (27, 52) and reciprocally with the progressive decrease in 
expression from haploinsufficiency to hypomorphic Pkd1 allele in mice (23, 25, 42, 53). In fact, both 
human ADPKD and murine Pkd1 studies have provided evidence for, although opposite, gain-of-
function as well as loss-of-function and haploinsufficiency/dosage effect as pathogenetic mechanisms. 
Hence, a Pkd1 dose imbalance model mechanism would be compatible with a dominantly inherited 
mutation as seen in humans and could also explain the high prevalence of ADPKD in the population. 
Importantly, the cystic focal nature in our Pkd1TAG study as in human ADPKD, supports a pathogenetic 
mechanism that combines Pkd1 dysregulation with an additional mutational step or stochastic 
event/threshold level to determine whether a cell will enter a cystic cascade and develop cystogenesis. 
 
This study demonstrates that “wild type” full-length Pkd1 overexpression/gain-of-function in the 
Pkd1TAG mouse is sufficient to reproduce the ADPKD systemic clinical manifestations. Enhanced Pkd1 
gene expression recapitulates a physiologic bona fide murine ADPKD disorder with renal and extrarenal 
phenotypes. Thus, these transgenic mice may be instrumental for numerous studies including the design 
of novel therapeutic strategies to modulate in vivo progression of ADPKD. 
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MATERIALS AND METHODS 
Constructs for homologous recombination of Pkd1-BAC clone 
The Pkd1-BAC clone from the bacterial host strain DH10B (RecA-; RecBC+) was isolated from a 
129/Sv mouse pBelo11BAC library (Research Genetics) and was orthologous to the human PKD1 gene 
as described in (27). To modify the original wild-type Pkd1-BAC by homologous recombination, two 
constructs were produced in the pLD53.SC-AB BAC recombination vector (54). The first construct was 
carried out in order to introduce a silent point mutation by substitution of a G to A nucleotide as we did 
for SBPkd1TAG (27). This substitution created a new EcoRI restriction site in Pkd1 exon 10 that 
distinguished the transgene from the endogenous gene/transcript. The second construct was performed 
to delete Tsc2 gene body and consisted of two homology arms, the Tsc2 promoter-intron 2 linked 
directly to Tsc2 exon 42-exon 46 Pkd1 in a BAC recombination vector. The first homology arm was 
obtained by PCR amplification of 1116bp fragment (Tsc2 promoter-intron2) with the primers: 5’-
TCAGATGCTGCGGCCCGGGACGCA-3’ (forward Tsc2 promoter) and 5’-
GGACAGCATGCCCTATGCAGATG (reverse intron2) followed by a restriction enzyme digest SmaI-
SpHI. The second arm was also generated from a PCR product of 1.2kb with the following primers: 5’-
TTCAGCACATGCTCATGCC-3’ (reverse Tsc2 intron 40) and 5’-
GCTGAAAATGGGCCCATTGTTACC-3’ (forward Pkd1 exon 46) followed by a SpHI- BamHI 
restriction digest that produce 0.9kb from Tsc2 exon42 to exon46 Pkd1. Both these arms were 
introduced into the pLD53.SC-AB BAC recombination vector. 
 
Modification of BAC clones by homologous recombination in E. coli 
Each of the two BAC recombination vectors was used in a two-step RecA strategy for BAC 
modifications, as previously described (27). Approximately 64 co-integrates were analyzed for each 
recombination by Southern blot to monitor for appropriate integration event. Two proper co-integrates 
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were chosen for the second recombination event and positive clones from the resolved BACs were 
further analyzed by Southern following standard and PFGE using seven probes spanning the entire 
sequence of the modified BAC. The probes were designed in (14, 27): a. genomic exon 1, b. genomic 
exon 2-3, c. genomic exon 7-15, d. cDNA exon 15-20, e. cDNA exon 25-34, f. cDNA exon 36-45, g. 
genomic exon 45-46. Subsequently, modified Pkd1 gene regions were sequenced to confirm that the 
intended recombined BAC clones were achieved. Following these two modifications the BAC clone was 
referred as Pkd1TAG-BAC. 
 
Production and analysis of Pkd1TAG-BAC transgenic mice 
The Pkd1TAG-BAC (40-50 µg of DNA) was digested with the restriction enzymes MluI and NotI. The 
~75kb transgene fragment was isolated on low melt agarose by PFGE. The Pkd1TAG linearized DNA 
fragment was purified as in (27). The fragment preparation was verified for integrity by PFGE and was 
microinjected as described (28). Transgenic founder mice and progenies were identified by Southern 
analysis of DNA from tail biopsies digested with HindIII, EcoRI and/or KpnI and respectively 
hybridized with the 7 mouse Pkd1 probes to verify integrity of the transgene. The 5’ transgene integrity 
was verified by a polymorphism at 4.47 kb of the murine Pkd1 gene specific for 129/sv that can be 
distinguished from the C57BL/6J and CBA/J inbred strains that served to produce the transgenic mice. 
PCR amplification of genomic DNA from transgenic mice at the polymorphic region was carried out 
with the primers: (forward) 5’-CTGCACCCATGTCAGGTGTA-3’ and (reverse) 5’-
GTTCTAGGCCAGCCAACTC-3’ and expected fragment for 129sv, C57Bl6/J and CBA/J are 100bp, 
133bp, and 113bp respectively. All transgenic mouse lines were backcrossed onto C57Bl6/J. Animal 
procedures were approved by the Animal Care Committee of the IRCM and conducted according to the 
guidelines of the Canadian Council on Animal Care. 
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RNA expression analysis 
Total RNA was extracted from various tissues, including kidneys, lungs, spleen, brain, heart, pancreas 
and liver, of 4 to 9 month old animals using guanidium thiocyanate or trizol/chloroform method (55). 
The integrity of all RNA preparations was monitored by electrophoresis on formaldehyde-agarose gels 
prior to analysis (56). 
 
Pkd1TAG transgene expression in all tissues was analyzed by quantitative real-time PCR. All RNA 
samples were reversed transcribed as previously described (10). The primers used were as follows: 5’- 
TCAATTGCTCCGGCCGCTG- 3’ (forward Pkd1 exon 1) and 5’-
CCAGCGTCTGAAGTAGGTTGTGGG-3’ (reverse Pkd1 exon 2) that detect endogenous and 
transgene. The S16 ribosomal gene product served as an internal control with the following primers: 5’-
AGGAGCGATTT-GCTGGTGTGGA-3’ (forward S16 exon 3) and 5’-
GCTACCAGGCCTTTGAGATGGA-3’ (reverse S16 exon 4). Each pair of primers was designed such 
that only spliced mRNA would produce the predicted amplification products of 101bp for Pkd1 total 
(endogenous gene and transgene) and 102bp for S16. All reactions for quantitative real-time PCR 
analysis were performed in triplicate in a master mix (Qiagen, Mississauga, Canada) using a MX4000 
Multiplex quantitative PCR analyser. 
 
Expression analysis of Pkd1 (endogenous gene and transgene) was also performed by Northern blot. 
Total RNA from each sample (30 µg) was electrophoresed on agarose/formaldehyde gel, transferred to 
nylon membranes and hybridized with “g” probe for Pkd1 and with glyceraldehyde 3-phosphate 
dehydrogenase (Gapdh) as internal control (14). Membranes were exposed to X-ray film (Biomax MS) 
for 24-48 hours, scanned and quantified with the Image Quant 5.0 software. 
 
23 
 
Protein expression analysis  
Total protein extracts from multiple organs, kidney, lung, brain, liver, pancreas and heart, were produced 
in RIPA buffer (20mM Tris pH8; 2mM EDTA; 150mM NaCl; Triton 0.5%) supplemented by cocktail of 
inhibitors of proteases (1X, SIGMA) and PMSF (1mM). Protein concentration was measured by 
Bradford assay (BioRad). Total protein extracts (40 or 80µg) was reduced in NuPAGE loading dye for 
7min at 65°C and loaded on 4-12% NuPage Bis-Tris gel using 1X MES SDS Invitrogen migration 
buffer. Urinary proteins were prepared as described (32, 33). In brief, urine was supplemented with 
cocktail inhibitors, centrifuged to remove cell debris and supernatant was considered total urinary 
fraction (T). Total fraction was then centrifuged, the new supernatant is the S1 fraction and pellet 
resuspended for recentrifugation, resulting in non-clustered uromodulin (S2) in the supernatant and the 
exosomes (Exo) in the pellet. Total urinary and S1 fractions (50ug) were precipitated by trichloroacetic 
acid and resuspended in loading dye. Exosomes were directly resuspended in loading dye with half the 
volume analyzed under the native form and the other half following deglycosylation with 750U of 
PNGase (New England Biolabs). Proteins were transferred on PVDF membranes that were hybridized 
with mouse monoclonal antibodies, 7e12 against N-terminal of polycystin-1 (51) and secondary goat 
anti-mouse IgG (SIGMA) coupled to horseradish peroxidase or with mouse monoclonal antibody Gapdh 
(Abcam, Cambridge, MA) and revealed with Amersham ECL Advance Plus (GE HealthCare) on X-
Omat films. 
  
Renal and Cardiac physiological function analysis 
Renal function was evaluated by analysis of urine samples collected in metabolic cages for 24 hours 
with non-restricted water supply. Urinary urea nitrogen, creatinine and ion concentrations were 
measured with a CX9 Beckmann apparatus whereas urine osmolality was determined with a radiometer. 
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Proteinuria was qualitatively analyzed using 50 µg of total urinary protein on a 10 % SDS-PAGE 
stained with Coomassie blue as described (57). 
Echocardiographic measurements on transgenic and control mice were carried out using the Vevo 770 
(Visualsonics) with a probe transducer of 35MHz as in (58). Preheated ultrasound transmisson gel 
(Aquasonic 100) was placed on heart region to provide acoustic coupling between the probe and the 
mice.  Cardiac dimensions including aortic root and left ventricle wall thickness and diameter were 
monitored in the M-mode. Functional analysis of stroke volume and cardiac output was determined from 
aortic Doppler measurements whereas the heart rate was obtained from ECG. Mitral and aortic valvular 
velocities upstream and downstream were measured using Doppler to evaluate their functional 
efficiency. 
  
Morphologic, histologic, and cellular analysis  
Different tissues including kidneys, heart, pancreas, lung, liver, brain, spleen were analyzed from adult 
transgenic mice aged between 1 to 20 months. Four-µm-thick paraffin sections of paraformaldehyde- or 
formalin-fixed tissues were deparaffinized and stained with hematoxylin and eosin. Detection of calcium 
deposits was monitored with specific stains by Alizarin red or Von Kossa and fibrosis by Sirius red. 
 
Cysts from renal tissue were immunostained to identify the origin of the nephron segment affected. 
Sections (4-µm) were incubated with three primary antibodies α-calbindin (Sigma) for collecting ducts, 
lycopersicon esculentum lectin (Vector Lab) for distal convoluted tubules and lotus tetragonolobus 
lectin linked to fluorescein (Vector Lab) for proximal tubules and then with secondary antibodies a goat 
α-mouse IgG Alexa 255 (Invitrogen) and AMCA-streptavidin (Vector Lab). Slides were visualized with 
Axiovert S100TV microscope. Characterization of primary cilia in renal tissues was performed with α-
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acetylated tubulin (Sigma) as primary antibody and goat α-mouse IgG Alexa 255 (Invitrogen) as 
secondary antibody and slides were mounted with vectashield and DAPI. 
 
Analysis of cellular c-myc expression and proliferation using Ki67 marker was performed by 
immunohistochemistry (59). Kidney and liver adult mice fixed tissues from transgenic and control mice 
were incubated with rabbit c-myc (Upstate) or rabbit Ki67 (Novocastra) O/N at 40C, then for 1 hour with 
secondary anti-rabbit biotinylated antibody and signal detected using Vectastain ABC kit (Vector Lab) 
and diaminobenzinide. Proliferation rate was evaluated according to the number of renal tubules normal 
(control) or cystic (Pkd1TAG) with 0, 1,  ≥2 nuclei positive for Ki67 on multiple non-overlapping images 
(≥5) using Axiophot (Zeiss) microscope. 
 
Vasculature analysis was performed from anesthetized animals perfused intracardiac with 
paraformaldehyde and Microfil media (Flow Tech Inc, Mass). Fixation was carried out overnight and 
tissues collected were cleared with methyl salicylate and photograph with Nikon SMZ-U using Q-
capture software. 
 
Statistical analysis 
Values were expressed as mean ± standard deviation. A 2-tailed unpaired Student’s t-test was used for 
statistical analysis; p < 0.05 was considered significant.  
26 
 
ACKNOWLEDGMENTS 
We thank Dr. V. Gattone and the Indiana University School of Medicine EM Center and the generous 
support of that facility by the Polycystic Kidney Disease Foundation. The authors thank K. Jani for 
technical support and Dr C. Deschepper for critical reading of the manuscript. This work was supported 
by the Canadian Institutes of Health Research (CIHR) [MOP-81325 to MT] and a CIHR Frederick 
Banting and Charles Best studentship to AK and a Fonds de la Recherche en Santé du Québec (FRSQ) 
studentship to MC.  
 
REFERENCES 
1. Chapman, A.B., Rubinstein, M.D., Hughes, R., Stears, J.C., Earnest, M.P., Johnson, 
A.M., Gabow, P.A. and Kaehny, W.D. (1992) Intracranial aneurysms in autosomal 
dominant polycystic kidney disease. N. Engl. J. of Med., 327, 916-920. 
2. Wei, W., Hackmann, K., Xu, H., Germino, G. and Qian, F. (2007) Characterization of 
cis-autoproteolysis of polycystin-1, the product of human polycystic kidney disease 1 
gene. J. Biol. Chem., 282, 21729-21737. 
3. Ward, C.J., Turley, H., Ong, A.C.M., Comley, M., Biddolph, S., Chetty, R., Ratcliffe, 
P.J., Gatter, K. and Harris, P.C. (1996) Polycystin, the polycystic kidney disease 1 
protein, is expressed by epithelial cells in fetal, adult and polycystic kidney. Proc. Natl. 
Acad. Sci. USA, 93, 1524-1528. 
4. Ong, A.C.M., Ward, C.J., Butler, R.J., Biddolph, S., Bowker, C., Torra, R., Pei, Y. and 
Harris, P.C. (1999) Coordinate expression of the autosomal dominant polycystic kidney 
disease proteins, polycystin-2 and polycystin-1, in normal and cystic tissue. Am. J. 
Pathol., 154, 1721-1729. 
27 
 
5. Geng, L., Segal, Y., Peissel, B., Deng, N., Pei, Y., Carone, F., Rennke, H.G., 
Glücksmann-Kuis, A.M., Schneider, M.C., Ericsson, M. et al. (1996) Identification and 
localization of polycystin, the PKD1 gene product. J. Clin. Invest., 98, 2674-2682. 
6. Ibraghimov-Beskrovnaya, O., Dackowski, W.R., Foggensteiner, L., Coleman, N., Thiru, 
S., Petry, L.R., Burn, T.C., Connors, T.D., Van Raay, T., Bradley, J. et al. (1997) 
Polycystin: In vitro synthesis, in vivo tissue expression, and subcellular localization 
identifies a large membrane-associated protein. Proc. Natl. Acad. Sci. USA, 94, 6397-
6402. 
7. Chauvet, V., Qian, F., Boute, N., Cai, Y., Phakdeekitacharoen, B., Onuchic, L.F., Attie-
Bitach, T., Guicharnaud, L., Devuyst, O., Germino, G.G. et al. (2002) Expression of 
PKD1 and PKD2 Transcripts and Proteins in Human Embryo and during Normal Kidney 
Development. Am. J. Pathol., 160, 973-983. 
8. Peters, D.J.M., Van De Wal, A., Spruit, L., Saris, J.J., Breuning, M.H., Bruijn, J.A. and 
de Heer, E. (1999) Cellular Localization and Tissue Distribution of Polycystin-1. J. 
Pathol., 188, 439-446. 
9. Trudel, M. and Guillaume, R. (2000) Molecular biology of autosomal dominant 
polycystic kidney disease. Pediatr. Pathol. Mol. Med., 18, 483-499. 
10. Lanoix, J., D'Agati, V., Szabolcs, M. and Trudel, M. (1996) Dysregulation of cellular 
proliferation and apoptosis mediates human autosomal dominant polycystic kidney 
disease (ADPKD). Oncogene, 13, 1153-1160. 
11. Qian, F., Watnick, T.J., Onuchic, L.F. and Germino, G.G. (1996) The molecular basis of 
focal cyst formation in human autosomal dominant polycystic kidney disease type I. Cell, 
87, 979-987. 
28 
 
12. Brasier, J.L. and Henske, E.P. (1997) Loss of the polycystic kidney disease (PKD1) 
region of chromosome 16p13 in renal cyst cells supports a loss-of-function model for 
cyst pathogenesis. J. Clin. Invest., 99, 194-199. 
13. Koptides, M., Constantinides, R., Kyriakides, G., Hadjigavriel, M., Patsalis, P.C., 
Pierides, A. and Deltas, C.C. (1998) Loss of heterozygosity in polycystic kidney disease 
with a missense mutation in the repeated region of PKD1. Hum. Genet., 103, 709-717. 
14. Guillaume, R., D'Agati, V., Daoust, M. and Trudel, M. (1999) Murine Pkd1 is a 
developmentally regulated gene from morula to adulthood: Role in tissue condensation 
and patterning. Dev. Dyn., 214, 337-348. 
15. Guillaume, R. and Trudel, M. (2000) Distinct and common developmental expression 
patterns of the murine PKD2 and PKD1 genes. Mech. Dev., 93, 179-183. 
16. Boulter, C., Mulroy, S., Webb, S., Fleming, S., Brindle, K. and Sandford, R. (2001) 
Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 
gene. Proc. Natl. Acad. Sci. USA, 98, 12174-12179. 
17. Kim, K., Drummond, I., Ibraghimov-Beskrovnaya, O., Klinger, K. and Arnaout, M.A. 
(2000) Polycystin 1 is required for the structural integrity of blood vessels. Proc. Natl. 
Acad. Sci. USA, 97, 1731-1736. 
18. Lu, W., Peissel, B., Babakhanlou, H., Pavlova, A., Geng, L., Fan, X., Larson, C., Brent, 
G. and Zhou, J. (1997) Perinatal lethality with kidney and pancreas defects in mice with a 
targetted PKD1 mutation. Nat. Genet., 17, 179-181. 
19. Lu, W., Shen, X., Pavlova, A., Lakkis, M., Watrd, C.J., Pritchard, L., Harris, P.C., 
Genest, D.R., Perez-Atayde, A.R. and Zhou, J. (2001) Comparison of Pkd1-targeted 
mutants reveals that loss of polycystin-1 causes cystogenesis and bone defects. Hum. 
Mol. Genet., 10, 2385-2396. 
29 
 
20. Muto, S., Aiba, A., Saito, Y., Nakao, K., Nakamura, K., Tomita, K., Kitamura, T., 
Kurabayashi, M., Nagai, R., Higashihara, E. et al. (2002) Pioglitazone improves the 
phenotype and molecular defects of a targeted Pkd1 mutant. Hum. Mol. Genet., 11, 1731-
1742. 
21. Wu, G., Tian, X., Nishimura, S., Markowitz, G.S., D'Agati, V., Park, J.H., Yao, L., Li, L., 
Geng, L., Zhao, H. et al. (2002) Trans-heterozygous Pkd1 and Pkd2 mutations modify 
expression of polycystin kidney disease. Hum. Mol. Genet., 11, 1845-1854. 
22. Starremans, P.G., Li, X., Finnerty, P.E., Guo, L., Takakura, A., Neilson, E.G. and Zhou, 
J. (2008) A mouse model for polycystic kidney disease through a somatic in-frame 
deletion in the 5' end of Pkd1. Kidney Int., 73, 1394-1405. 
23. Lantinga-van Leeuwen, I.S., Leonhard, W.N., van der Wal, A., Breuning, M.H., de Heer, 
E. and Peters, D.J.M. (2007) Kidney-specific inactivation of the Pkd1 gene induces rapid 
cyst formation in developing kidneys and a slow onset of disease in adult mice. Hum. 
Mol. Genet., 16, 3188-3196. 
24. Takakura, A., Contrino, L., Beck, A.W. and Zhou, J. (2008) Pkd1 inactivation induced in 
adulthood produces focal cystic disease. J. Am. Soc. Nephrol., 19, 2351-2363. 
25. Lantinga-van Leeuwen, I.S., Dauwerse, J.G., Baelde, H.J., Leonhard, W.N., van de Wal, 
A., Ward, C.J., Verbeek, S., Deruiter, M.C., Breuning, M.H., de Heer, E. et al. (2004) 
Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease. Hum. Mol. 
Genet., 13, 3069-3077. 
26. Lu, W., Fan, X., Basora, N., Babakhanlou, H., Law, T., Rifai, N., Harris, P.C., Perez-
Atayde, A.R., Rennke, H.G. and Zhou, J. (1999) Late onset of renal and hepatic cysts in 
Pkd1-targeted heterozygotes. Nat. Genet., 21, 160-161. 
30 
 
27. Thivierge, C., Kurbegovic, A., Couillard, M., Guillaume, R., Cote, O. and Trudel, M. 
(2006) Overexpression of PKD1 Causes Polycystic Kidney Disease. Mol. Cell. Biol., 26, 
1538-1548. 
28. Trudel, M., D'Agati, V. and Costantini, F. (1991) C-myc as an inducer of polycystic 
kidney disease in transgenic mice. Kidney Int., 39, 665-671. 
29. Torres, V.E., Erickson, S.B., Smith, L.H., Wilson, D.M., Hattery, R.R. and Segura, J.W. 
(1988) The association of nephrolithiasis and autosomal dominant polycystic kidney 
disease. Am. J. Kidney Dis., 11, 318-325. 
30. Torres, V.E., Wilson, D.M., Hattery, R.R. and Segura, J.W. (1993) Renal stone disease in 
autosomal dominant polycystic kidney disease. Am. J. Kidney Dis., 22, 513-519. 
31. Levine, E. and Grantham, J.J. (1992) Calcified renal stones and cyst calcifications in 
autosomal dominant polycystic kidney disease: clinical and CT study in 84 patients. Am. 
J. Roentgenol., 159, 77-81. 
32. Gonzales, P.A., Pisitkun, T., Hoffert, J.D., Tchapyjnikov, D., Star, R.A., Kleta, R., Wang, 
N.S. and Knepper, M.A. (2009) Large-scale proteomics and phosphoproteomics of 
urinary exosomes. J. Am. Soc. Nephrol., 20, 363-379. 
33. Hogan, M.C., Manganelli, L., Woollard, J.R., Masyuk, A.I., Masyuk, T.V., Tammachote, 
R., Huang, B.Q., Leontovich, A.A., Beito, T.G., Madden, B.J. et al. (2009) 
Characterization of PKD protein-positive exosome-like vesicles. J. Am. Soc. Nephrol., 
20, 278-288. 
34. Adeney, K.L., Siscovick, D.S., Ix, J.H., Seliger, S.L., Shlipak, M.G., Jenny, N.S. and 
Kestenbaum, B.R. (2009) Association of serum phosphate with vascular and valvular 
calcification in moderate CKD. J. Am. Soc. Nephrol., 20, 381-387. 
31 
 
35. Yoder, B.K., Hou, X. and Guay-Woodford, L.M. (2002) The Polycystic Kidney Disease 
Proteins, Polycystin-1, Polycystin-2, Polaris, and Cystin, Are Co-Localized in Renal 
Cilia. J. Am. Soc. Nephrol., 13, 2508-2516. 
36. Pazour, G.J., Dickert, B.L., Vucica, Y., Seeley, E.S., Rosenbaum, J.L., Witman, G.B. and 
Cole, D.G. (2000) Chlamydomonas IFT88 and its mouse homologue, polycystic kidney 
disease gene tg737, are required for assembly of cilia and flagella. J. Cell. Biol., 151, 
709-718. 
37. Lin, F., Hiesberger, T., Cordes, K., Sinclair, A.M., Goldstein, L.S.B., Somlo, S. and 
Igarashi, P. (2003) Kidney-specific inactivation of the KIF3A subunit of kinesin-II 
inhibits renal ciliogenesis and produces polycystic kidney disease. Proc. Natl. Acad. Sci. 
USA, 100, 5286-5291. 
38. Masyuk, T.V., Huang, B.Q., Ward, C.J., Masyuk, A.I., Yuan, D., Splinter, P.L., 
Punyashthiti, R., Ritman, E.L., Torres, V.E., Harris, P.C. et al. (2003) Defects in 
cholangiocyte fibrocystin expression and ciliary structure in the PCK rat. 
Gastroenterology, 125, 1303-1310. 
39. Smith, L.A., Bukanov, N.O., Husson, H., Russo, R.J., Barry, T.C., Taylor, A.L., Beier, 
D.R. and Ibraghimov-Beskrovnaya, O. (2006) Development of polycystic kidney disease 
in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and 
common features with human disease. J. Am. Soc. Nephrol., 17, 2821-2831. 
40. Cadieux, C., Harada, R., Paquet, M., Cote, O., Trudel, M., Nepveu, A. and Bouchard, M. 
(2008) Polycystic kidneys caused by sustained expression of Cux1 isoform p75. J. Biol. 
Chem., 283, 13817-13824. 
41. Pisitkun, T., Shen, R.F. and Knepper, M.A. (2004) Identification and proteomic profiling 
of exosomes in human urine. Proc. Natl. Acad. Sci. U S A, 101, 13368-13373. 
32 
 
42. Jiang, S.-T., Chiou, Y.-Y., Wang, E., Lin, H.-K., Lin, Y.-T., Chi, Y.-C., Wang, C.-K.L., 
Tang, M.-J. and Li, H. (2006) Defining a Link with Autosomal-Dominant Polycystic 
Kidney Disease in Mice with Congenitally Low Expression of Pkd1. Am. J. Pathol., 168, 
205-220. 
43. Trudel, M. and D'Agati, V. (1992) A model of polycystic kidney disease in SBM 
transgenic mice. In Berlyne, G.M. (ed.), Contrib. Nephrol. Karger, S., Basel, Brooklyn, 
NY, Vol. 97, pp. 47-59. 
44. Griffin, M.D., Torres, V.E., Grande, J.P. and Kumar, R. (1996) Immunolocalization of 
polycystin in human tissues and cultured cells. Proc. Assoc. Am. Physicians, 108. 
45. Leier, C.V., Baker, P.B., Kilman, J.W. and Wooley, C.F. (1984) Cardiovascular 
abnormalities associated with adult polycystic kidney disease. Ann. Intern. Med., 100, 
683-688. 
46. Hossack, K.F., Leddy, C.L., Johnson, A.M., Schrier, R.W. and Gabow, P.A. (1988) 
Echocardiographic findings in autosomal dominant polycystic kidney disease. The New 
England Journal of Medicine, 319, 907-912. 
47. Griffin, M.D., Torres, V.E., Grande, J.P. and Kumar, R. (1997) Vascular Expression of 
Polycystin. J. Am. Soc. Nephrol., 8, 616-626. 
48. Peters, D.J.M., Spruit, L., Klingel, R., Prins, F., Baelde, H.J.J., Giordano, P.C., Bernini, 
L.F., de Heer, E., Breuning, M.H. and Bruijn, J.A. (1996) Adult, fetal, and polycystic 
kidney expression of polycystin, the polycystic kidney disease-1 gene product. Lab. 
Invest., 75, 221-230. 
49. Weston, B.S., Jeffery, S., Jeffrey, I., Sharaf, S.F.A., Carter, N., Saggar-Malik, A. and 
Price, R.G. (1997) Polycystin expression during embryonic development of human 
kidney in adult tissues and ADPKD tissue. Histochem. J., 29, 847-856. 
33 
 
50. Palson, R., Sharma, C.P., Kim, K., McLaughlin, M., Brown, D. and Arnaout, M.A. 
(1996) Characterization and cell distribution of polycystin, the product of autosomal 
dominant polycystic kidney disease gene 1. Mol. Med., 2, 702-711. 
51. Ong, A.C.M., Harris, P.C., Davies, D.R., Pritchard, L., Rossetti, S., Biddolph, S., Vaux, 
D.J.T., Migone, N. and Ward, C.J. (1999) Polycystin-1 expression in PKD1, early onset 
PKD1 and TSC2/PKD1 cystic tissue: implications for understanding cystogenesis. 
Kidney Int., 56, 1324-1333. 
52. Pritchard, L., Sloane-Stanley, J.A., Sharpe, J.A., Aspinwall, R., Lu, W., Buckle, V., 
Strmecki, L., Walker, D., Ward, C.J., Alpers, C.E. et al. (2000) A human PKD1 
transgene generates functional polycystin-1 in mice and is associated with a cystic 
phenotype. Hum. Mol. Genet., 9, 2617-2627. 
53. Ahrabi, A.K., Terryn, S., Valenti, G., Caron, N., Serradeil-Le Gal, C., Raufaste, D., 
Nielsen, S., Horie, S., Verbavatz, J.M. and Devuyst, O. (2007) PKD1 haploinsufficiency 
causes a syndrome of inappropriate antidiuresis in mice. J. Am. Soc. Nephrol., 18, 1740-
1753. 
54. Gong, S., Yang, X.W., Li, C. and Heintz, N. (2002) Highly Efficient Modification of 
Bacterial Artificial Chromosomes (BACs) Using Novel Shuttle Vectors Containing the 
R6Kγ Origin of Replication. Genome Res., 12, 1992-1998. 
55. Couillard, M., Guillaume, R., Tanji, N., D'Agati, V. and Trudel, M. (2002) c-myc-
induced Apoptosis in Polycystic Kidney Disease is Independent of FasL/Fas Interaction. 
Cancer Res., 62, 2210-2214. 
56. Trudel, M., Lanoix, J., Barisoni, L., Blouin, M.-J., Desforges, M., L'Italien, C. and 
D'Agati, V. (1997) C-myc-induced Apoptosis in Polycystic Kidney Disease is Bcl-2 and 
p53 Independent. J. Exp. Med., 186, 1873-1884. 
34 
 
57. De Paepe, M.E. and Trudel, M. (1994) The transgenic SAD mouse: A model of human 
sickle cell glomerulopathy. Kidney Int., 46, 1337-1345. 
58. Stoyanova, E., Trudel, M., Felfly, H., Garcia, D. and Cloutier, G. (2007) Characterization 
of circulatory disorders in beta-thalassemic mice by noninvasive ultrasound 
biomicroscopy. Physiol. Genomics, 29, 84-90. 
59. Couillard, M. and Trudel, M. (2009) C-myc as a modulator of renal stem/progenitor cell 
population. Dev. Dyn., 238, 405-414. 
 
35 
 
FIGURE LEGENDS 
Figure 1 Genomic analysis of Pkd1 TAG transgenic mice 
Representative analysis of the 5’ regulatory region of Pkd1TAG transgenic mice was carried out based on 
a polymorphism at ~ 4.5 kb upstream of the translation initiation codon of the murine Pkd1 gene. Since 
Pkd1TAG transgenic mice were produced on a mixed C57Bl6/J and CBA/J inbred background, the BAC 
of 129sv origin could be detected by 100bp amplification band whereas the C57Bl6/J and CBA/J 
displayed a 133 and 113bp, respectively. Analysis of the 3’ Pkd1TAG region was verified on Southern 
using a KpnI digestion with the Pkd1 "g" probe (exon 45-46). Bands are expected at 7kb for the 
endogenous Pkd1 gene and at 5kb for the Pkd1TAG transgene (5kb). The 5’ and the 3’ ends of the 
transgene were intact for the three transgenic mouse lines. M: 100 bp marker; C: negative control; C57: 
C57Bl/6J mice; CBA: CBA/J mice; 129:129sv mice; Ma: lambda HindIII marker; WT: wild type control 
mice; Tg: Pkd1TAG transgene; Endo: endogenous Pkd1 gene; E: EcoRI; K: Kpnl; E* = tag silent point 
mutation. 
 
Figure 2 Expression analysis of Pkd1 TAG transgenic mice 
(A) Renal expression analysis of total Pkd1 (endogenous and transgene: ~14.2kb) transcript of Pkd1TAG 
transgenic mice assessed by Northern blotting using Pkd1 probe "f" (exon 36-45) and Gapdh (1.2 kb). 
One representative kidney sample from each transgenic line 6, 18 and 26 is compared to endogenous 
Pkd1 transcript of control (C) genetic background and age-matched mice. Quantification of renal 
transcripts from transgenic Pkd1TAG mouse lines were increased compared to endogenous Pkd1 
transcript as indicated below the blot (control refers to 1). 
(B) Quantitative real-time PCR of Pkd1 expression from renal and extrarenal tissues was carried out 
using primers in exons 1 and 2. Transgenic mice (n=3; * n= 2) from each of the 3 different lines and 
non-transgenic age-matched control mice (4-12 mo) were analyzed in triplicata for Pkd1 and S16 that 
served as an internal control. Quantification of renal expression in these transgenic mice ranged from 1.3 
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to 15.5-fold relative to endogenous levels of control mice arbitrarily set at 1. Extrarenal tissue 
expression levels were established in function of Pkd1 levels in control kidneys. Number in parentheses 
refers to the ratio of transgene expression levels to the organ control. Similar gene expression ratio or 
fold-increase was detected for each transgenic line across the tissues analyzed. 
(C) Renal and extrarenal polycystin-1 protein expression analysis in Pkd1TAG 26 mice (6 mo.) by 
Western blot using the N-terminal Pc-1 7e12antibody. In Pkd1TAG organs, Pc-1 expression was intact 
and at higher expression levels than controls (6 mo.). Of the organs tested, highest Pc-1 signal was 
detected in lungs, heart and kidney. Quantities of protein loaded (40 or 80 ug prot) are indicated below 
the blot. C: non-transgenic control mice; Tg: Pkd1TAG transgenic mice, line 26. Gapdh was used as an 
internal loading control. 
 
Figure 3 Renal phenotype in Pkd1TAG mice 
(A, B) Overview of renal cortical sections from adult 20 month-old control and Pkd1TAG6 mice, 
respectively. While control exhibited normal glomeruli (g) and tubule (t), Pkd1TAG6 mice showed 
presence of numerous glomerular and tubular cysts associated with frequent proteinaceous casts (pc) and 
of tubulointerstitial fibrosis (H&E). Original magnification, x10.  
(C, D) High power view of renal sections of Pkd1TAG6 and 26 mice (26 and 16 mo.) that show epithelial 
hyperplasia and hypertrophy (H) as well as presence of polyps (arrowhead) in cystic tubules. Original 
magnification, x 40.  
(E, F) Assessment of nephron segment origin in control and Pkd1TAG26 mice (7 mo.) respectively was 
determined by immunofluorescence using specific markers of proximal (Lotus tetragonolobus, green), 
distal (Esculentum Lycopersicon, blue) and collecting ducts (α-Calbindin D28K, red). Transgenic mice 
displayed cysts from all nephron segments and in higher proportion in proximal and collecting tubules. 
Noticeably, epithelial hyperplasia and hypertrophy (H) were frequently observed in dilated collecting 
ducts. Original magnification, x20. 
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(G, H) Analysis of calcium deposits from renal sections of control and Pkd1TAG26 (10 mo.) respectively 
was evaluated by Alizarin red staining. Intense extracellular calcium deposits were detected in the renal 
papilla of Pkd1TAG26 mice (inset) but absence of signal in cysts or in kidneys of non-transgenic mice. 
Original magnification, x10. 
(I, J) Proliferation was assessed from control and Pkd1TAG26 renal sections (13 mo.) respectively with 
the Ki67 nuclear proliferation marker. Epithelial cells from normal and dilated tubules displayed higher 
rate of proliferation in Pkd1TAG26 mice compared to control. Original magnification, x40. 
(K, L) Detection of c-myc in renal tissues of control and Pkd1TAG6 (13 mo.) respectively correlated with 
higher proliferation rate. Increased nuclear and even cytoplasmic staining in cystic and non-cystic 
regions in Pkd1TAG6 relative to control. Original magnification, x40. 
(M, N) Primary cilia of renal epithelial cells from control and Pkd1TAG mice (1 mo.) respectively 
were assessed. Triplet figure consists of staining by α-acetylated tubulin (left panel) marker for 
cilia, DAPI (middle panel) for nucleus and merge (right panel). In control mice, the average 
length of cilia was estimated to 2-3 µm whereas in Pkd1TAG26 mice a significant shift in cilia 
length distribution to longer cilia of ≥ 5 µm was measured. Original magnification, x100. 
 
Figure 4 Analysis of urinary proteins in Pkd1TAG mice 
(A) Protein urine samples from all Pkd1TAG mice lines (4 mo.) were compared to non-transgenic age-
matched control (C) and SBM transgenic mice (positive control that develop PKD) in addition to serum 
protein sample (S) from non-transgenic mice on SDS-PAGE stained by Coomassie blue. Albumin 
normally present in serum was detected at abnormally high levels in Pkd1TAG26 urine comparable to 
SBM urine. Pkd1TAG mice like SBM mice exhibit non-selective proteinuria. Mice also displayed normal 
excretion of the major urinary proteins (MUPs). M: molecular mass markers of 31 to 200 kDa.  
(B) Polycystin-1 was analyzed in fractioned urinary samples by Western blot using the N-terminal 7e12 
Pc-1 antibody. Two bands (slightly above ~420kDa and ~360-380kDa) were typically detected in native 
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(N, without treatment) samples whether from total kidney protein extracts of Pkd1TAG26, from total 
urinary proteins (T) or exosome-free fraction (S1) of Pkd1TAG26 and of control mice (mean ~9 mo.). A 
unique Pc-1 band slightly above ~420kDa was observed in exosome (Exo) fractions from Pkd1TAG and 
control urine whereas the uromodulin-positive (S2) fraction appears devoided of Pc-1. Noticeably, 
Pkd1TAG transgenic mice in comparison to age-matched control mice consistently showed more intense 
Pc-1 bands and likely higher Pc-1 excretion. Upon deglycosylation (DG) of protein extracts with 
PNGase, a unique band is detected at the size of the lowest native band (~360-380kDa), showing strong 
glycosylation of Pc-1 and indicating that the band above ~420kDa is likely the cleaved form of Pc-1 
(predicted mass of 448kDa and 328kDa in glycosylated and deglycosylated respectively).  
Figure 5 Pkd1TAG mice hepatic phenotypes 
(A, B) Macroscopic view of livers is shown from adult control and Pkd1TAG 26 mice (20 mo.) 
respectively. In comparison to normal liver of control mice, liver of Pkd1TAG mice appeared abnormal 
with clusters of cysts. Original magnification, x5.  
(C, D) Overview of liver histologic sections from adult control and Pkd1TAG26 mice (14 and 23 mo.), 
respectively. Notably, a Pkd1TAG mouse shows presence of numerous cysts (c) lined by cuboid 
epithelium, suggesting tubular cholangiocyte origin. Cluster of cysts are formed focally around the 
periportal region tubular structures (H&E). Original magnification, x10. 
(E, F) Liver sections from adult control and Pkd1TAG26 mice (11and 14 mo.), respectively. Liver of 
Pkd1TAG mice displayed severe periportal fibrosis with various levels of increased interstitial fibrosis 
(Sirius red). Original magnification, x10.  
(G, H) Proliferation was assessed from liver sections of control and Pkd1TAG26 (21 mo.) respectively 
with the Ki67 nuclear proliferation marker. Cystic epithelium of the liver was associated with higher rate 
of proliferation compared to non-cystic control. Original magnification, x40. 
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(I, J) Analysis of c-myc in hepatic tissues of control and Pkd1TAG26 (16 and 23 mo.) respectively 
correlated with higher proliferation rate. Increased nuclear and even cytoplasmic staining is observed in 
cystic regions in Pkd1TAG relative to control. Original magnification, x40. 
 Figure 6 Cardiac phenotypes in Pkd1TAG mice 
(A, B) Non-invasive ultrasound of cardiac function of adult control mice and Pkd1TAG 26 mice (16 mo.), 
respectively. Echocardiography of Pkd1TAG mice detected presence of aortic valve of hyperechoic, 
indicating calcification and probably stenosis (white arrow). Attached video imaging shows the inability 
of the aortic valves to fully open. 
(C, D) Anatomy of hearts from adult control mice and Pkd1TAG mice (8 and 7 mo.), respectively. The 
heart size of Pkd1TAG mice (0.32g and body weight 16.7g) is readily larger than non-transgenic control 
(0.27g and body weight 31.5g). Original magnification, x2.5.  
(E, F) Heart vasculature from adult control mice and Pkd1TAG 26 mice (11 and 13 mo.) respectively, 
filled with Microfil latex. Pkd1TAG mouse left ventricle hypertrophy was clearly visible under 3D angles 
by different segmentation and the substantial decreased vascularization of ventricular wall (*). 
(G, H) Longitudinally sectioned heart from adult control and Pkd1TAG mice (11 and 12 mo.), 
respectively. View of sectioned heart of Pkd1TAG 26 mouse displays changes in color pigmentation of 
the left ventricle wall (arrow) due to calcium deposits as defined with specific histology stains. Original 
magnification, x5.  
(I, J) Higher-power view of aortic valves from adult control and Pkd1TAG mice (11 and 12 mo.), 
respectively. Pkd1TAG mouse exhibited severe calcified valves (arrow) stained with Alizarin red 
consistent with echocardiography. Original magnification, x20. 
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Figure 7 Pkd1TAG mice vascular defect: intracranial aneurysm. 
(A, B) Macroscopic view of scalped head is shown from adult control and Pkd1TAG26 mice (1 mo.) 
respectively. Evidence of enlarged skull associated with abnormal brain/ventricle morphology, sagital 
suture, intracranial hemorrhages and edema in Pkd1TAG mice.  
(C, D) Overview of brain sections from adult control and Pkd1TAG mice (1 mo.), respectively. Evidence 
of Pkd1TAG cortex (c) thinning is shown with a major cavity associated with elongated and compressed 
cerebellum (ce) due to hemorrhage and excessive fluid (H&E). Original magnification, x1.25.  
(E, F) Brain vasculature from adult control mice and Pkd1TAG 26 mice (11 and 13 mo.) 
respectively filled with Microfil latex. Evidence of unruptured cerebral aneurysm (arrow) was 
observed in a Pkd1TAG mouse whereas not detected in vasculature of control mice. Original 
magnification, x5. 
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Table 1 
A) Urine Analysis 
Mice* Age 
(mo) 
n Volume 
(mL) 
n Urea Nitrogen 
(mmol/L) 
n Creatinine 
(mmol/L) 
n Protein  
(g/L) 
n Osmolality 
(mOsm/kg) 
Control 16 5 0.5 ± 0.2 5 682 ± 407 5 4.9 ± 0.6 5 1.4 ± 0.8 5 2026 ± 160 
Pkd1TAG 6 15 6 1.6 ± 0.5b 6  309 ± 148 c 6 1.1 ± 0.3d 6 0.7 ± 0.3 6   627 ± 166d 
Control 4-9 12 0.7 ± 0.4 12 809 ± 320 15 3.9 ± 1.8 11 6.9 ± 5.5 11 1426 ± 547 
SBM 4-10 10  2.7 ± 1.3b 7 328 ± 76c 8 1.3 ± 0.6c 5 3.4 ± 1.4 4   843 ± 265a 
Pkd1TAG 26 5-7 7  2.4 ± 1.5b 8  461 ± 267a 10 1.6 ± 1.3b 8 1.1 ± 0.7b 6 985 ± 566 
*Urine analysis of Pkd1TAG with control mice at severe renal phenotype time points. 
a P≤0.02; b P≤0.01; c P≤0.001; d P≤0.0001   
 
B) Blood Analysis 
Mice Age 
(mo) 
n Hematocrit
(%) 
n BUN 
range (mmol/L) 
Creatinine 
(mmol/L) 
Sodium 
(mmol/L) 
Osmolality 
(mOsm/kg) 
Control 6 5 54 ± 3 5 6.3 – 8.4 
(mean 7.5 ± 0.8) 
19.6 ± 2.6 151 ± 2 329 ± 5 
Pkd1TAG 6 15 6  40 ± 3e 6 9.0 – 12.8 20.1 ± 3.2  157 ± 2d  340 ± 4b 
Pkd1TAG 26 6 7  35 ± 6c 8 5.5 – 10.8 29.8 ± 7.5b  156 ± 2b  336 ± 6a 
a P≤0.05; b P≤0.005; c P≤0.001; d P≤0.0005; e P≤0.0001 
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Table 2 
A) Cardiac Dimension Analysis 
      Echocardiographic measurement 
     
 
         
     
 
  
Mice 
   
Heart wt/
Body wt  
Left 
ventricle 
pw 
 
Inter-
ventricular
septum 
 Aortic root  
Left  
ventricle 
volume 
 
Ventricle 
diameter 
        d s  d s  diam. area  d s  d s 
    %    10-2 mm/wt  10-2 mm/wt  10-2 mm/wt   µl/wt   10-2 mm/wt 
  n    n                
Control  21  0.7 
±0.1 
 6
 
2.0 
±0.3 
2.8 
±0.6 
 2.1 
±0.4 
3.0 
±0.5 
 
3.5 
±0.2 
4.1 
±0.3 
 2.21 
±0.23 
1.01 
±0.24 
 10.7 
±0.7 
7.7 
±0.9 
                      
Pkd1TAG6  26  0.9
a 
±0.3 
 6
 
3.8c 
±0.6 
 5.1d 
±0.7 
  3.6d
±0.4 
4.9d 
±0.5 
 
5.0b 
±0.8 
5.3a
±1.0 
 2.17 
±0.35 
0.73 
±0.23 
 13.9
c 
±1.2 
8.8 
±1.1 
                      
Pkd1TAG26  27  1.0
e 
±0.2 
 4
 
3.3c 
±0.4 
4.6b 
±0.6 
 3.2a 
±0.6 
4.0 
±1.3 
 
5.0d 
±0.2 
5.7d 
±0.2 
  3.11 
±1.06 
1.51 
±0.97 
  15.2
a 
±2.4 
10.9 
±3.0 
a P≤0.05; b P≤0.003; c P≤0.002; d P≤0.0002; e P≤10-6 
wt = weight; pw = posterior wall; d = diastolic; s = systolic; diam. = diameter  
 
B) Echocardiographic Functional Analysis 
  
 
           
 
 
     
Aortic valve  
velocity  
Mitral valve  
velocity 
Mice 
 
 
Stroke 
vol.  
aorta  
Fractional   
ejection  
Fractional 
shortening 
 
Cardiac 
output 
 
Heart 
rate  Upstream  Downstream  Upstream  Downstream 
    
         mean peak  mean peak  mean peak  mean peak  
   10-2 mL/wt  %  %  ml/min/wt  bpm  mm/s  mm/s  mm/s  mm/s 
 n   
    
    n   n   n   n   
Control 6 
 
0.27 
±0.03 
 54.8 
±6.5 
 28.5 
±4.3  
1.29 
±0.16 
 474 
±16 
4 554 
±56 
977 
±140 
6 1152 
±134 
1901 
±247 
4 557 
±79 
899 
±105 
6 743 
±77 
1247 
±133 
                        
Pkd1TAG6 6 
 
0.31 
±0.06 
  66.6b 
±8.1 
  36.4b 
±6.2  
1.49 
±0.32 
 482 
±22 
6 486 
±104 
776 
±170 
6 1155 
±343 
1861 
±565 
6 511 
±74 
851 
±135 
6 800 
±117 
1318 
±208 
                        
Pkd1TAG26 4 
 
 0.53b 
±0.13 
 53.6 
±17.1 
 28.5 
±12.2  
 2.59c 
±0.46 
 487 
±43 
4 581 
±251 
965 
±431 
4  1705a
±344 
 2772a 
±562 
4 454 
±103 
817 
±156 
4 714 
±109 
1233 
±205 
a P≤0.05; b P≤0.03; c P≤0.01 
bpm = beats per minute
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Mice n Pkd1 expression relative to control kidneys (relative to organ control) 
  Kidneys Brain Heart Lungs Spleen Liver Pancreas 
Control 3   1.0   3.5  (1.0)   1.5  (1.0)   2.9 (1.0) 0.5 (1.0) 0.6 (1.0) 0.8  (1.0) 
Pkd1TAG 6 3   1.3   5.6  (1.6)   2.3  (1.5)   3.1 (1.1) 0.7 (1.4) 0.8 (1.2) 1.0  (1.2) 
Pkd1TAG 18 3   8.0 24.7  (7.1) 13.6  (8.8) 13.9 (4.9) 3.5 (6.6) 3.2 (5.3) 3.0  (3.6) 
Pkd1TAG 26 3 15.5 37.7 (10.8)  20.6 (13.3) 22.6 (7.9) 5.8 (11.0) 5.3 (8.7)  10.9 (13.2) *
A 
C 
B 
Figure 2 
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List of Abbreviations 
 
ADPKD autosomal dominant polycystic kidney disease 
Gapdh glyceraldehyde 3-phosphate dehydrogenase 
GPS G-protein coupled receptor proteolytic site 
Pc-1 Pkd1 protein or polycystin-1 
 
 
 
 
 
 
 
